Psilocybin-assisted therapy produced rapid depression improvements within days to weeks across major depressive disorder trials, including 54% remission at day 14 in one 52-person trial and significant benefit through 43 days in a 104-person trial. Longer follow-up showed 75% response and 58% remission at 12 months in one MDD cohort, while treatment-resistant depression data showed the clearest controlled signal at 25 mg, including 37% response and 29.1% remission at 3 weeks in a 233-person trial. Benefits were strongest when psilocybin was delivered with preparation, supervised dosing, and integration, with mostly transient side effects like anxiety, nausea, headache, dizziness, and brief blood pressure or heart-rate increases.